Centene and CVS Health Announce Agreement for CVS Health to Acquire IlliniCare Health

美国连锁药房巨头CVS将收购IlliniCare Health

2019-12-03 18:30:15 YAHOO!FINANCE

本文共6419个字,阅读需17分钟

 Centene Corporation and CVS Health  announced today that, in connection with the previously announced merger agreement between Centene and WellCare Health Plans, Inc. , Centene has entered into a definitive agreement under which CVS Health will acquire Centene's Illinois health plan subsidiary, IlliniCare Health Plan, Inc. . The transaction entails the sale of Centene's Medicaid and Medicare Advantage lines of business in Illinois. Centene will retain IlliniCare's Medicare-Medicaid Alignment Initiative ("MMAI") business and IlliniCare's statewide YouthCare foster care contract, set to commence in February 2020. Centene's Ambetter business in Illinois is not affected. The companies are committed to ensuring that there is a smooth transition for members. "We are continuing to make progress towards completing our transaction with WellCare and the divestiture of our IlliniCare Health plan is the next step in that process," said Michael F. Neidorff, Centene's Chairman, President and Chief Executive Officer. "Our employees in Illinois have done an exceptional job serving our communities in the state. We are pleased to enter this agreement with CVS Health, under which these employees can continue helping members achieve better health outcomes while delivering benefits to providers. We will work closely with CVS Health to ensure a smooth transition of this business for members, employees and providers." "Expanding our Medicaid and Medicare Advantage presence in Illinois will allow us to serve more members with our proven holistic approach that addresses physical, behavioral and social determinants of care," said Karen S. Lynch, Executive Vice President, CVS Health and President, Aetna. "We look forward to working with Centene on a seamless transition and developing a deeper relationship with the state and local providers." The closing of the transaction with CVS Health is subject to U.S. federal antitrust clearance, receipt of Illinois state regulatory approvals and other customary closing conditions, as well as the closing of the Centene – WellCare transaction. As previously announced on March 27, 2019, Centene and WellCare agreed to combine in a transaction that will create a premier healthcare enterprise focused on government-sponsored healthcare programs and a leader in Medicaid, Medicare and the Health Insurance Marketplace. The combination has received approvals from insurance and health care departments from 26 states. Completion of the Centene – WellCare transaction remains subject to clearance under the Hart-Scott-Rodino Act, receipt of required state regulatory approvals and other customary closing conditions. Centene and WellCare continue to expect that the Centene – WellCare transaction will be completed by the first half of 2020. The financial terms of this transaction will not be disclosed and the impact to CVS Health earnings once closed is expected to be immaterial. Additional information about the Centene – WellCare transaction can be found at centene-wellcare.com. About CenteneCentene Corporation, a Fortune 100 company, is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children's Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long-Term Services and Supports (LTSS), in addition to other state-sponsored programs, Medicare (including the Medicare prescription drug benefit commonly known as "Part D"), dual eligible programs and programs with the U.S. Department of Defense. Centene also provides healthcare services to groups and individuals delivered through commercial health plans. Centene operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, commercial programs, home-based primary care services, life and health management, vision benefits management, pharmacy benefits management, specialty pharmacy and telehealth services. Centene uses its investor relations website to publish important information about the company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://www.centene.com/investors. About CVS HealthCVS Health is the nation's premier health innovation company helping people on their path to better health. Whether in one of its pharmacies or through its health services and plans, CVS Health is pioneering a bold new approach to total health by making quality care more affordable, accessible, simple and seamless. CVS Health is community-based and locally focused, engaging consumers with the care they need when and where they need it. The Company has more than 9,800 retail locations, approximately 1,100 walk-in medical clinics, a leading pharmacy benefits manager with approximately 93 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan. CVS Health also serves an estimated 39 million people through traditional, voluntary and consumer-directed health insurance products and related services, including a rapidly expanding Medicare Advantage offering. This innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com. Cautionary Statement on Forward-Looking Statements of CenteneAll statements, other than statements of current or historical fact, contained in this communication are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). In particular, these statements include, without limitation, statements about Centene's future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of Centene's proposed acquisition of WellCare Health Plans, Inc. (the "WellCare Transaction"), Centene's recent acquisition (the "Fidelis Care Transaction") of substantially all the assets of New York State Catholic Health Plan, Inc., d/b/a Fidelis Care New York ("Fidelis Care"), investments and the adequacy of Centene's available cash resources. These forward-looking statements reflect Centene's current views with respect to future events and are based on numerous assumptions and assessments made by us in light of Centene's experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors Centene believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause Centene's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this filing are based on information available to us on the date of this communication. Except as may be otherwise required by law, Centene undertakes no obligation to update or revise the forward-looking statements included in this communication, whether as a result of new information, future events or otherwise, after the date of this filing. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to, the following: (i) the risk that regulatory or other approvals required for the WellCare Transaction may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management's time and Centene's resources or otherwise have an adverse effect on Centene; (ii) the possibility that certain conditions to the consummation of the WellCare Transaction will not be satisfied or completed on a timely basis and accordingly the WellCare Transaction may not be consummated on a timely basis or at all; (iii) uncertainty as to the expected financial performance of the combined company following completion of the WellCare Transaction; (iv) the possibility that the expected synergies and value creation from the WellCare Transaction will not be realized, or will not be realized within the expected time period; (v) the exertion of management's time and Centene's resources, and other expenses incurred and business changes required, in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for the WellCare Transaction; (vi) the risk that unexpected costs will be incurred in connection with the completion and/or integration of the WellCare Transaction or that the integration of WellCare will be more difficult or time consuming than expected; (vii) the risk that potential litigation in connection with the WellCare Transaction may affect the timing or occurrence of the WellCare Transaction or result in significant costs of defense, indemnification and liability; (viii) a downgrade of the credit rating of Centene's indebtedness, which could give rise to an obligation to redeem existing indebtedness; (ix) unexpected costs, charges or expenses resulting from the WellCare Transaction; (x) the inability to retain key personnel; (xi) disruption from the announcement, pendency and/or completion of the WellCare Transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; and (xii) the risk that, following the WellCare Transaction, the combined company may not be able to effectively manage its expanded operations. Additional factors that may cause actual results to differ materially from projections, estimates, or other forward-looking statements include, but are not limited to, the following: (i) Centene's ability to accurately predict and effectively manage health benefits and other operating expenses and reserves; (ii) competition; (iii) membership and revenue declines or unexpected trends; (iv) changes in healthcare practices, new technologies, and advances in medicine; (v) increased healthcare costs, (vi) changes in economic, political or market conditions; (vii) changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the Affordable Care Act ("ACA"), and any regulations enacted thereunder that may result from changing political conditions or judicial actions, including the ultimate outcome of the District Court decision in "Texas v. United States of America" regarding the constitutionality of the ACA; (viii) rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting Centene's government businesses; (ix) Centene's ability to adequately price products on federally facilitated and state-based Health Insurance Marketplaces; (x) tax matters; (xi) disasters or major epidemics; (xii) the outcome of legal and regulatory proceedings; (xiii) changes in expected contract start dates; (xiv) provider, state, federal and other contract changes and timing of regulatory approval of contracts; (xv) the expiration, suspension, or termination of Centene's contracts with federal or state governments (including but not limited to Medicaid, Medicare, TRICARE or other customers); (xvi) the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; (xvii) challenges to Centene's contract awards; (xviii) cyber-attacks or other privacy or data security incidents; (xix) the possibility that the expected synergies and value creation from acquired businesses, including, without limitation, the Fidelis Care Transaction, will not be realized, or will not be realized within the expected time period; (xx) the exertion of management's time and Centene's resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions, including the Fidelis Care Transaction; (xxi) disruption caused by significant completed and pending acquisitions, including, among others, the Fidelis Care Transaction, making it more difficult to maintain business and operational relationships; (xxii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions, including, among others, the Fidelis Care Transaction; (xxiii) changes in expected closing dates, estimated purchase price and accretion for acquisitions; (xxiv) the risk that acquired businesses, including Fidelis Care, will not be integrated successfully; (xxv) the risk that, following the Fidelis Care Transaction, Centene may not be able to effectively manage its expanded operations; (xxvi) restrictions and limitations in connection with Centene's indebtedness; (xxvii) Centene's ability to maintain the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; (xxviii) availability of debt and equity financing, on terms that are favorable to us; (xxxix) inflation; and (xxx) foreign currency fluctuations. This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect Centene's business operations, financial condition and results of operations, in Centene's filings with the Securities and Exchange Commission (the "SEC"), including the registration statement on Form S-4 filed by Centene with the Securities and Exchange Commission on May 23, 2019 (the "Registration Statement"), and Centene's Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, Centene cannot give assurances with respect to Centene's future performance, including without limitation Centene's ability to maintain adequate premium levels or Centene's ability to control its future medical and selling, general and administrative costs. Important Additional Information and Where to Find ItIn connection with the WellCare Transaction, on May 23, 2019, Centene filed with the SEC the Registration Statement, which included a prospectus with respect to the shares of Centene's common stock to be issued in the WellCare Transaction and a joint proxy statement for Centene's and WellCare's respective stockholders (the "Joint Proxy Statement"). The SEC declared the Registration Statement effective on May 23, 2019, and the Joint Proxy Statement was first mailed to stockholders of Centene and WellCare on or about May 24, 2019. Each of Centene and WellCare may file other documents regarding the WellCare Transaction with the SEC. This communication is not a substitute for the Registration Statement, the Joint Proxy Statement or any other document that Centene or WellCare may send to their respective stockholders in connection with the WellCare Transaction. INVESTORS AND SECURITY HOLDERS OF CENTENE AND WELLCARE ARE URGED TO READ THE REGISTRATION STATEMENT, THE JOINT PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT CENTENE, WELLCARE, THE WELLCARE TRANSACTION AND RELATED MATTERS. Investors and security holders of Centene and WellCare are able to obtain free copies of the Registration Statement, the Joint Proxy Statement and other documents (including any amendments or supplements thereto) containing important information about Centene and WellCare through the website maintained by the SEC at www.sec.gov. Centene and WellCare make available free of charge at www.centene.com and www.ir.wellcare.com, respectively, copies of materials they file with, or furnish to, the SEC. No Offer or SolicitationThis communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. View original content:http://www.prnewswire.com/news-releases/centene-and-cvs-health-announce-agreement-for-cvs-health-to-acquire-illinicare-health-300967193.html SOURCE Centene Corporation
Centene Corporation 与 CVS Health 今日宣布,就此前宣布的 Centene 与 WellCare Health Plans , Inc .之间的合并协议, Centene 已签订最终协议, CVS Health 将收购 Centene 在伊利诺伊州的健康计划子公司 IlliniCare Health Plan , Inc .。该交易包括出售 Centene 的 Medicaid 和 Medicare Advantage 业务在伊利诺伊州。 Centene 将保留 IlliniCare 的 Medicare-Medicaid alignment Initiative (" MMAI ")业务和 IlliniCare 的全州 YouthCare 寄养服务合同,该合同将于2020年2月开始生效。Centene 在伊利诺伊州的 Ambetter 业务不受影响。这些公司致力于确保成员平稳过渡。 Centene 董事长、总裁兼首席执行官 Michael F . Neidorff 说:“我们在完成与 WellCare 的交易方面继续取得进展,剥离我们的非法医疗保健计划是这一进程的下一步。”“我们在伊利诺伊州的雇员为我们在该州的社区服务,做了一项杰出的工作。我们很高兴与 CVS Health 签订该协议,根据该协议,这些员工可以继续帮助成员实现更好的健康结果,同时为提供者提供福利。我们将与 CVS 健康部门密切合作,确保该业务顺利过渡到会员、员工和提供商。” CVS 健康执行副总裁兼 Aetna 总裁 Karen S.Lynch 说:“扩大我们在伊利诺伊州的医疗补助和医疗保险优势,将使我们能够以我们行之有效的整体方法为更多的成员服务,解决医疗保健的物理、行为和社会决定因素。”“我们期待着与 Centene 合作,实现无缝过渡,并与国家和地方供应商建立更深层次的关系。” 与 CVS Health 达成的交易须获得美国联邦反垄断机构的批准、伊利诺伊州监管机构的批准和其他惯例成交条件,以及 Centene-WellCare 交易的完成。 正如之前在2019年3月27日宣布的, Centene 和 WellCare 同意在一项交易中合并,这项交易将创建一个专注于政府赞助的医疗保健计划的一流医疗保健企业,并成为 Medicaid 、 Medicare 和健康保险市场的领导者。这一合并已经获得了来自26个州的保险和医疗部门的批准。Centene – WellCare 交易的完成仍需根据 Hart-Scott-Rodino 法案进行审批,并收到所需的州监管机构批准和其他惯例的成交条件。 Centene 和 WellCare 继续预计 Centene – WellCare 交易将于2020年上半年完成。 本次交易的财务条款将不予披露,一旦完成对 CVS Health 盈利的影响预计不大。 关于 Centene – WellCare 事务的其他信息可以在 Centne-Wellcare 中找到。com 。 关于 CenteneCentene 公司,一家财富100强公司,是一家多元化的、多国的医疗企业,为政府资助的和商业的医疗保健项目提供一揽子服务,重点关注未投保和未投保的个人。许多人领取根据医疗补助计划提供的福利,包括国家儿童健康保险计划( CHIP ),以及老年人、盲人或残疾人( ABD )、寄养和长期服务与支持( LTSS ),以及其他国家资助的计划,医疗保险(包括通常称为“ D 部分”的医疗保险处方药福利)。与美国国防部的双重合格计划。Centene 还通过商业健康计划为团体和个人提供医疗服务。Centene 运营当地的健康计划,并提供一系列健康保险解决方案。它还与其他医疗和商业组织签订合同,提供专业服务,包括行为健康管理、护理管理软件、矫正保健服务、牙科福利管理、商业计划、家庭初级保健服务、生活和健康管理、视力福利管理、药房效益管理,专科药房和远程保健服务。 Centene 利用其投资者关系网站发布有关公司的重要信息,包括可能被视为对投资者有实质性影响的信息。Centene 的财务和其他信息定期发布,可在 Centene 的投资者关系网站 http://www.Centne.com/investors 上查阅。 关于 CVS 健康 CVS 健康是美国首屈一指的健康创新公司,帮助人们走上更健康的道路。无论是在一家药店,还是通过它的健康服务和计划, CVS 健康正在开创一种大胆的新方法,通过使高质量的保健更加负担得起,容易获得,简单和无缝。CVS Health 以社区为基础,以当地为重点,让消费者在他们需要的时候和地点享受他们需要的护理。本公司拥有9,800多家零售门店,约1,100家门诊诊所,一家拥有约9,300万计划会员的领先药店福利经理,一家专注的高级药店护理业务,每年为超过100万患者提供服务,拓展特色药店服务。以及领先的独立 Medicare Part D 处方药计划。CVS Health 还通过传统、自愿和消费者导向的健康保险产品及相关服务,包括迅速扩大的 Medicare Advantage 产品,为大约3900万人提供服务。这种创新的保健模式增加了获得优质保健的机会,提供更好的保健成果,并降低总体保健费用。有关 CVS Health 如何塑造健康未来的更多信息,请访问 https://www.cvheeth.com 。 Centene 前瞻性陈述的谨慎声明除了当前或历史事实陈述外,本函件中包含的所有陈述均为前瞻性陈述。在不限制前述内容的前提下,前瞻性陈述经常使用诸如“相信”、“预期”、“计划”、“预期”、“估计”、“意图”、“寻求”、“目标”、“可能”、“会”、“会”、“应该”、“能够”、“继续”等词语或表达(以及它们的否定)。特别是,这些报表包括但不限于关于 Centene 未来经营或财务业绩、市场机会、增长战略、竞争、已完成和未来收购的预期活动的报表,包括关于 Centene 拟收购 WellCare Health Plan 影响的报表。Inc .(“ WellCare Transaction ”), Centene 最近收购纽约州天主教健康计划有限公司( d / b / a Fidelis Care New York ,简称“ Fidelis Care ”)几乎所有资产(“ Fidelis Care Transaction ”),投资以及 Centene 可用现金资源的充分性。 这些前瞻性陈述反映了 Centene 目前对未来事件的看法,并基于我们根据 Centene 的经验和对历史趋势、当前状况、业务战略、运营环境的看法所作出的众多假设和评估。Centene 认为未来的发展和其他因素是适当的。根据其性质,前瞻性陈述涉及已知和未知的风险和不确定性,并可能因与事件相关而发生变化,并取决于未来将发生的情况,包括经济、监管、竞争和其他可能导致 Centene 或其行业实际结果、活动水平的因素。业绩或成就与这些前瞻性陈述所表达或暗示的任何未来成果、活动水平、业绩或成就有重大差异。这些报表不是对未来业绩的保证,受制于风险、不确定性和假设。 本文件中包含的所有前瞻性陈述均基于我们在本函件日期获得的信息。除法律另有规定外, Centene 承诺在本次备案日后,不会因新的信息、未来事件或其他原因而更新或修改本函件所包含的前瞻性陈述。您不应过度依赖任何前瞻性陈述,因为实际结果可能因各种重要因素、变量和事件(包括但不限于以下各项:( i )根据不预期可能需要动用管理层的时间和 Centene 的资源或以其他方式对 Centene 产生不利影响的条件, WellCare Transaction 所需的监管或其他批准可能被延迟或未获得或获得的风险;( ii )未能及时满足或完成 WellCare Transaction 的某些条件,因此 WellCare Transaction 可能无法及时或全部完成;( iii ) WellCare Transaction 完成后合并公司预期财务业绩的不确定性;( iv ) Centene 在遵守交易、承诺和时间内不会产生预期协同效应和价值变化的可能性;政府或第三方同意或批准 WellCare 交易;( vi )与完成和/或整合 WellCare 交易相关的意外成本或整合 WellCare 将比预期更困难或更耗时的风险;( vii )与 WellCare 交易相关的潜在诉讼可能影响 WellCare 交易的时间或发生,或导致重大的辩护、赔偿和责任成本;( viii )降低 Centene 债务的信用评级,从而可能导致赎回现有债务;( ix ) WellCare 交易导致的意外成本、收费或费用;( x )无法留住关键人员;( xi )公告WellCare Transaction 的暂停和/或完成,包括潜在的不利反应或与客户、员工、供应商或监管机构的业务关系变化,使维持业务和运营关系变得更加困难;以及( xii )在 WellCare Transaction 之后,合并后的公司可能无法有效管理其扩展的运营的风险。 可能导致实际结果与预测、估计或其他前瞻性陈述存在重大差异的其他因素包括但不限于:以下方面:( i ) Centene 准确预测和有效管理健康福利和其他运营费用和储备的能力;( ii )竞争;( iii )会员和收入下降或意外趋势;( iv )医疗实践、新技术和医疗进步的变化;( v )医疗成本增加;( vi )经济、政治或市场条件变化;( vii )联邦或州法律或法规的变化;包括与所得税改革或政府保健方案有关的变化,以及与《病人保护和负担得起的照护法》和《保健和教育负担得起的和解法案》有关的变化,统称为《负担得起的照护法》(" ACA "),以及根据该法案颁布的可能因政治条件或司法行动变化而产生的任何条例,包括地区法院在"德克萨斯诉美利坚合众国"一案中就 ACA 的合宪性作出的裁决的最终结果;㈧利率削减或政府付款人的其他付款削减或延迟,以及影响 Centene 政府业务的其他风险和不确定性;㈨ Centene 在联邦便利和基于州的医疗保险市场充分定价产品的能力;( x )税务事项;( xi )灾害或重大流行病;( xii )法律和监管程序的结果;( xiii )预期合同开始日期的变更;( xiv )提供者、州、联邦和其他合同的变更和批准合同的时间;( xv ) Centene 联邦医疗保险合同的终止、暂停或终止TRICARE 或其他客户);( xvi )难以预测未决或未来诉讼或政府调查的时间或结果;( xvii )对 Centene 合同授予的质疑;( xvii )网络攻击或其他隐私或数据安全事件;( xix )收购业务(包括但不限于 Fidelis Care Transaction )预期协同效应和价值创造的可能性不会实现,或不会在预期时间内实现;( xx )管理层利用时间和 Centene 的资源,以及因遵守与任何监管相关的承诺而产生的其他费用和业务变更。政府或第三方同意或批准收购,包括 Fidelis Care Transaction ;( xxi )重大已完成和未决收购导致的中断,包括 Fidelis Care Transaction ,使维持业务和运营关系变得更加困难;( xxi )与完成和/或整合收购交易(包括 Fidelis Care Transaction )相关的意外成本将产生的风险;( xxi )预期截止日期、估计收购价格和收购增值的变化;( xxi )收购业务(包括 Fidelis Care )不成功整合的风险;( xxi )继 Fidelis Care Transaction 之后的风险。Centene 可能无法有效管理其扩大的运营;( xxx )与 Centene 债务相关的限制和限制;( xxx ) Centene 维持 Medicare 和 Medicaid 服务中心( CMS ) Star 评级的能力,以及在可能影响收入和未来增长的每种情况下维持或实现其他质量分数的提高;( xxxii )债务和股权融资的可用性,对我们有利的条款;( xxx )通货膨胀;以及( xxx )外币波动。 这一重要因素清单并非详尽无遗。我们在 Centene 提交给美国证券交易委员会(“ SEC ”)的文件中,更全面地讨论了其中某些事项,以及可能影响 Centene 业务运营、财务状况和运营结果的某些其他因素。包括 Centene 于2019年5月23日向证券交易委员会提交的表格 S-4的注册声明(“注册声明”),以及 Centene 关于10-K报表的年度报告、表格10-Q 的季度报告和表格8-K 的当前报告。由于这些重要因素和风险, Centene 不能对 Centene 未来的业绩作出保证,包括但不限于 Centene 维持足够的溢价水平的能力或 Centene 控制其未来医疗和销售、一般和行政成本的能力。 重要补充信息及在何处找到与 WellCare Transaction 有关的 Itene ,2019年5月23日, Centene 向 SEC 提交了《注册声明》,其中包括将于 WellCare Transaction 中发行的 Centene 普通股的招股章程以及 Centene 和 WellCare 各自股东的联合委托书(“联合委托书”)。SEC 宣布注册声明于2019年5月23日生效,联合委托书于2019年5月24日或前后首次邮寄至 Centene 和 WellCare 的股东。Centene 和 WellCare 各自可以向 SEC 提交关于 WellCare 交易的其他文件。该通信不能替代注册声明、联合代理声明或 Centene 或 WellCare 可能向各自股东发送的与 WellCare 交易有关的任何其他文件。中央和西部地区的投资者和证券持有人有权查阅登记报表,提交给美国证券交易委员会的联合方案声明和任何其他相关文件(包括任何修改或补充文件),只要这些文件由于中央、 WELLCARE 、 WELLCARE 交易和相关事项的影响或将包含重要信息,可全部提交给美国证券交易委员会。Centene 和 WellCare 的投资者和证券持有人可以通过 SEC 网站 www.sec.gov 获取包含 Centene 和 WellCare 重要信息的注册声明、联合代理声明和其他文件(包括其任何修订或补充文件)的免费副本。Centene 和 WellCare 分别在 www.Centne.com 和 www.ir.wellcare.com 上免费提供向 SEC 提交或提供的材料副本。 不提供或索取本通讯仅供参考之用,并不构成或构成销售要约或销售要约邀请或购买要约或购买任何证券要约邀请的一部分,且在该要约的任何司法管辖区内不得出售证券,根据任何此类司法管辖区的证券法,在登记或取得资格之前,招标或出售都是非法的。除通过符合1933年证券法(经修订)第10条规定的招股说明书或根据适用法律规定的其他方式外,不得进行证券要约。 查看原始内容: http://www.prnewswire.com/news-disease/centne-and-cvs-health-announcement-for-cvs-health-to-acquisition-illiciare-health-300967193。html SoURCE Centene 公司

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文